Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286265 | 0.88 | F2RL3 (0.38) | USP30UCHL1TSHRLMNAALDH1A1 | |
| SCHEMBL2286272 | 0.88 | F2RL3 (0.38) | USP30UCHL1TSHRLMNAALDH1A1 | |
| SCHEMBL2290596 | 0.75 | USP30 (0.43) | USP30OPRD1TSHRLMNAALDH1A1 | |
| SCHEMBL2290600 | 0.75 | USP30 (0.43) | USP30OPRD1TSHRLMNAALDH1A1 | |
| SCHEMBL5106523 | 0.67 | USP30 (0.43) | USP30 | |
| SCHEMBL5106527 | 0.67 | USP30 (0.43) | USP30 | |
| SCHEMBL5107240 | 0.63 | PDE4D (0.42) | USP30 | |
| SCHEMBL5107233 | 0.63 | PDE4D (0.42) | USP30 | |
| SCHEMBL2545927 | 0.62 | RIPK1 (0.46) | USP30UCHL1OPRD1GPR119 | |
| SCHEMBL4199082 | 0.61 | FFAR1 (0.47) | USP30UCHL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2163554-B1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2163554-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | USP30 4680/4885UCHL1 4785/4885OPRD1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.